Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Moodys
Medtronic
Dow
Johnson and Johnson
Chinese Patent Office
Cantor Fitzgerald
Merck
Cipla
McKinsey

Generated: December 12, 2017

DrugPatentWatch Database Preview

Metuchen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for METUCHEN PHARMS, and when can generic versions of METUCHEN PHARMS drugs launch?

METUCHEN PHARMS has one approved drug.

There are two US patents protecting METUCHEN PHARMS drugs on METUCHEN PHARMS drugs in the past three years.

There are fifty-three patent family members on METUCHEN PHARMS drugs in twenty-six countries and eight supplementary protection certificates in eight countries.

Summary for Metuchen Pharms

International Patents:53
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-002Apr 27, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-001Apr 27, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-003Apr 27, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-001Apr 27, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-003Apr 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-001Apr 27, 2012RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-001Apr 27, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-002Apr 27, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-002Apr 27, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Metuchen PharmsSTENDRAavanafilTABLET;ORAL202276-003Apr 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for METUCHEN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
avanafilTablets50 mg, 100 mg and 200 mgSTENDRA4/27/2016

Non-Orange Book Patents for Metuchen Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,797,709 Aromatic nitrogen-containing 6-membered cyclic compounds► Subscribe
7,273,868Pyrazine derivatives► Subscribe
7,220,736Pyrimidine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Metuchen Pharms Drugs

Country Document Number Estimated Expiration
South Africa200201499► Subscribe
Australia767558► Subscribe
Russian Federation2233273► Subscribe
Canada2420461► Subscribe
Austria358670► Subscribe
New Zealand522217► Subscribe
Hong Kong1044535► Subscribe
TaiwanI258471► Subscribe
Brazil0014526► Subscribe
Spain2283315► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Metuchen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13/041Ireland► SubscribePRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613
2013 00040Denmark► Subscribe
00618Netherlands► SubscribePRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
249Luxembourg► SubscribePRODUCT NAME: AVANAFIL
C0050France► SubscribePRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621
6Finland► Subscribe
2013000096Germany► SubscribePRODUCT NAME: AVANAFIL UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/13/841 20130621
90047-7Sweden► SubscribePRODUCT NAME: AVANAFIL; REG. NO/DATE: EU/1/13/841 20130621
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fuji
US Department of Justice
Deloitte
AstraZeneca
Novartis
Merck
Farmers Insurance
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot